{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Participants with locally advanced or metastatic ALK-positive tumors were to receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.","id":"OG000","title":"ALK-positive Solid Tumors"}],"populationDescription":"BICR was not performed.","reportingStatus":"POSTED","timeFrame":"0 days","title":"Confirmed ORR as Determined by Blinded Independent Center Review (BICR) Per RECIST v1.1","type":"SECONDARY"}